By-health(SZ:300146)2022-04-28 16:00Revenue and Profit - Revenue for Q1 2022 was CNY 2,280,271,630.40, an increase of 2.60% compared to CNY 2,222,500,945.10 in Q1 2021[3] - Net profit attributable to shareholders decreased by 18.78% to CNY 663,007,234.38 from CNY 816,301,215.48 year-on-year[3] - Basic earnings per share fell by 25.00% to CNY 0.39 from CNY 0.52 in the same period last year[3] - In Q1 2022, the company achieved a revenue of 2.28 billion RMB, a year-on-year increase of 2.60%, while the net profit attributable to shareholders was 663 million RMB, a decrease of 18.78%[12] - The revenue from the joint care brand "健力多" was 419 million RMB, a year-on-year decrease of 14.20%[12] - Total operating revenue for the current period reached ¥2,280,271,630.40, an increase from ¥2,222,500,945.10 in the previous period, representing a growth of approximately 2.6%[19] Cash Flow and Investments - Operating cash flow turned negative at CNY -45,114,075.46, a decline of 185.17% compared to CNY 52,971,907.24 in Q1 2021[3] - The net cash flow from investing activities was -310.89 million RMB, primarily due to increased purchases of large certificates of deposit and bank wealth management products[9] - The net cash flow from financing activities was 4.88 million RMB, mainly from bank borrowings during the reporting period[9] - The company reported a net profit margin decline, with undistributed profits at ¥1,505,139,162.43 compared to ¥2,037,285,483.27, a decrease of about 26%[18] - The net cash flow from operating activities is CNY -45,114,075.46, compared to CNY 52,971,907.24 in the previous period, indicating a significant decline[23] Assets and Liabilities - Total assets increased by 0.28% to CNY 13,001,869,436.10 from CNY 12,965,926,741.50 at the end of the previous year[3] - Current assets totaled ¥7,830,278,116.34, compared to ¥7,338,713,552.95 in the previous period, marking an increase of about 6.7%[15] - Total liabilities rose to ¥2,932,102,202.38 from ¥2,429,411,332.90, representing an increase of about 20.6%[17] - The total equity attributable to shareholders decreased to ¥10,025,482,965.84 from ¥10,493,948,552.08, a decline of about 4.5%[18] - The company’s total assets decreased from CNY 2,900,259,350.33 at the beginning of the period to CNY 2,551,326,587.08 at the end of the period, reflecting a decrease of 12%[24] Expenses - Research and development expenses increased by 101.23% to CNY 31,489,377.91, reflecting higher investment in R&D[8] - Sales expenses increased by 46.30% to CNY 589,892,571.31, mainly due to higher platform and brand promotion costs[8] - Total operating costs amounted to ¥1,433,031,690.49, up from ¥1,232,481,594.32, indicating a rise of about 16.3%[19] - The company incurred interest expenses of CNY 832,021.19, a significant decrease from CNY 3,052,947.15 in the previous period, indicating a reduction of 72.7%[20] Business Performance - Domestic business revenue for the main brand "汤臣倍健" was 1.29 billion RMB, a year-on-year decrease of 6.50%, while the "Life-Space" domestic products saw a revenue increase of 46.49% to 97 million RMB[12] - The overseas LSG business generated a revenue of 168 million RMB, a year-on-year increase of 25.28%, with a growth of 37.56% when measured in Australian dollars[12] - The company is focusing on enhancing operational quality and has initiated offline sales reforms and integrated online and offline operations[12] - The company is committed to advancing major projects across various operational aspects, including R&D, production, branding, and service[12] Investment Income - Investment income surged by 125.08% to CNY 32,502,622.36, primarily from large time deposits[8] - The company reported investment income of CNY 32,502,622.36, which is a substantial increase from CNY 14,440,254.18 in the previous period, representing an increase of 125.1%[20]